SecBot SecBot
SECBOTREPLAY Home › Report › VIR

VIR · Common stock offering launched

Vir Biotechnology, Inc. · 424B5 filed Nov 12, 2026 at 16:16 ET

At the news

BEARISHIMPACT 5/10

424B5 filed Nov 12, 2026 at 16:16 ET

Vir Biotechnology filed a preliminary prospectus supplement for an underwritten public offering of common stock, with size, price, and other terms left as placeholders. The offering follows positive Phase 3 ECLIPSE 1 data for its CHD program and a recent Gilead collaboration. Proceeds will fund pre-commercial activities for the CHD program, TCE oncology platform investments, and general corporate purposes.

  • Preliminary prospectus supplement for an underwritten common stock offering filed on November 12, 2026.
  • Share count, public offering price, underwriting discounts, and net proceeds are all placeholders (TBD).
  • Last reported sale price on November 11, 2026 was $13.13 per share.
  • Underwriters have a 30-day option to purchase additional shares.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access